



Canadian Association for  
Population Therapeutics

---

CONFERENCE

Association Canadienne pour la  
thérapeutique des populations

Facts, Figures, and the Art of  
Health Care Decision-Making:  
linking knowledge generation to  
health outcomes

.....

**P R O G R A M**

MARCH 28–30, 2010 | TORONTO, ONTARIO  
THE FOUR SEASONS HOTEL

## **CAPT MISSION & VISION**

The CAPT Mission is to advance population-based research of therapeutic interventions to improve the health outcomes of Canadians by:

- Bringing together diverse perspectives
- Facilitating open exchange of ideas and collaboration, and
- Influencing policy and practice

The CAPT Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice to optimize health outcomes.

## **CAPT 2010 SCIENTIFIC PLANNING COMMITTEE:**

Larry Lynd, University of British Columbia (Co-Chair)  
Carlo Marra, University of British Columbia (Co-Chair)  
Michael Iskedjian, PharmIdeas  
Lori-Jean Manness, Merck  
Nicole Mittmann, Health Outcomes & Pharmacoeconomics Research Centre  
Nancy Risebrough, Oxford Outcomes  
Angela Rocchi, Axia Research

## **CAPT 2010 LOCAL ORGANIZING COMMITTEE:**

Jackie Gladman, i3 Innovus (Chair)  
Alina Ciobanu, AstraZeneca  
Anna Liovas, AstraZeneca  
Michael Paterson, Institute for Clinical Evaluative Sciences  
Laurene Redding, Takeda Canada Inc.

[www.capt-actp.com](http://www.capt-actp.com)

## **Message from the President**

Welcome to the 2010 Canadian Association for Population Therapeutics (CAPT) / Association Canadienne pour la Thérapeutique des Populations (ACTP) annual conference! You are joining a wide diversity of academic researchers, federal and provincial policy-makers, pharmaceutical industry representatives and other experts in an open exchange of ideas and collaboration to advance population-based research of therapeutic interventions.

The past year has been an interesting one for CAPT as Board members continued the Strategic Planning Initiative. You will hear more about the actions coming from this initiative at the conference. Over the next few days, enjoy meeting and listening to Canadian and international experts, reviewing the posters, catching up with friends and colleagues, making new contacts, and attending an exciting social event at the Royal Ontario Museum.

Nigel Rawson  
CAPT President

## **CAPT 2010 Conference Overview**

Welcome to the 2010 CAPT/ACTP conference! The title of this year's conference, "Facts, Figures, and the Art of Health Care Decision-Making: linking knowledge generation to health outcomes" speaks to the need to translate the results from rigorous scientific investigation to health policy and decision-making . The Program Committee offers its sincere thanks to the sponsors who have made this conference possible.

The mission of CAPT/ACTP is to advance population-based research of therapeutic interventions to improve the health of Canadians by bringing together diverse perspectives, facilitating open exchange of ideas and collaboration, and influencing policy and practice. The Scientific Committee has designed the conference program to achieve this mission by inviting a wide variety of keynote speakers and panelists, by including more panel sessions than in previous conferences, and by balancing sessions in pharmacoepidemiology and health economics with others in health policy. In addition, we have many exciting contributed presentations and posters. We encourage you to maximize your opportunities for interaction and exchange of ideas throughout the three days with both old and new colleagues and friends, and hope that you enjoy the conference.

Carlo Marra & Larry Lynd  
Co-Chairs, Scientific Committee

# **“Facts, Figures, and the Art of Health Care Decision-Making: linking knowledge generation to health outcomes”**

---

**Sunday, March 28<sup>th</sup>, 2010**

---

**\*\* All Poster Presentations will be displayed in the Regency Ballroom West from  
12:00 h Sunday until Monday at 17:30 h \*\***

**08:00 – 17:00            Registration (Regency Foyer)**

**Pre-Conference Symposium  
Location: Regency Ballroom**

**09:00 – 12:00            CIHR’s Institute of Gender and Health Pre-Conference Symposium  
Advancing Population-Based Research on Therapeutic Interventions  
by Accounting for Sex and Gender (Pre-Registration Required)**

**Speakers:**

Steve Morgan, Associate Professor, School of Population and Public  
Health and Associate Director, Centre for Health Services and Policy  
Research, University of British Columbia, Vancouver  
Judith Soon, Assistant Professor, Faculty of Pharmaceutical Sciences,  
University of British Columbia, Vancouver  
Emma Spreekmeester, Drug Reviewer, Bureau of Metabolism, Oncology  
and Reproductive Sciences, Health Canada Therapeutic Products  
Directorate, Ottawa

**12:00 – 13:00            Hot Lunch & Contributed Poster Presentations  
Location: Regency Foyer & Regency Ballroom West  
(All conference registrants welcome)**

**Conference Commencement  
Location: Regency Ballroom**

**13:00 – 13:15            Opening Remarks & Welcome  
Nigel Rawson, GlaxoSmithKline Inc. and President, Canadian Association  
for Population Therapeutics**

**13:15 – 15:45            Health Policy Symposium (Sponsored by Merck)  
Future pharma: the evolving pharmaceutical environment and  
implications for research, policy and health outcomes**

**Introduction and Opening Remarks**

Lorne Tyrrell (Chair), CIHR/GSK Chair in Virology, University of Alberta  
and Board Chair, Institute of Health Economics, Edmonton

**Comparative Effectiveness Research and Personalized Medicine:  
Implications for the Future Pharmascape**

Clifford Goodman, Vice-President, The Lewin Group,  
Falls Church, Virginia

**Coping with a paucity of data: An evaluation framework for  
rare diseases**

Chaim Bell, Assistant Professor of Medicine and Health Policy,  
Management & Evaluation, University of Toronto, Toronto

**Balancing Evidence and Access for new Cancer Agents**

Terrence Sullivan, President and CEO, Cancer Care Ontario, Toronto

**Access and Innovation: A Private Payer's Perspective**

Amanda Ung, Product Director, Pharmaceutical Benefits,  
Sun Life Financial, Toronto

**15:45 – 16:15**

**Break & Contributed Poster Presentations**

**Location: Regency Foyer & Regency Ballroom West**

**16:15 – 17:30**

**Contributed Oral Presentations**

**Topics in Decision Making**

Chair: Angela Rocchi, Axia Research

**Ethnic disparities in prescription drug use: evidence from  
British Columbia**

S Morgan, University of British Columbia (Abstract 10)

**Surrogate outcomes in HTA decision making**

R Modha, Heron Evidence Development Ltd. (Abstract 13)

**Differences in EuroQol Five Dimension (EQ-5D) and Health Utilities  
Index 3 (HUI3) derived utility scores in an HIV population**

P Isogai, HOPE Research Centre, Sunnybrook Health Sciences Centre  
(Abstract 7)

**Seniors presenting to the Emergency Department after a fall: costs  
and consequences**

JC Woolcott, University of British Columbia (Abstract 12)

**Cost-effectiveness analysis of thiopurine methyltransferase testing  
to guide mercaptopurine starting doses in pediatric patients with  
acute lymphoblastic leukemia**

JR Donnan, Newfoundland and Labrador Centre for Health Information  
(Abstract 6)

---

**Sunday, March 28<sup>th</sup>, 2010**

---

**17:30 – 19:30**      **Reception & Contributed Poster Presentations**  
**(Sponsored by AstraZeneca Canada Inc.)**  
**Location: Regency Foyer & Regency Ballroom West**

---

**Monday, March 29<sup>th</sup>, 2010**

---

**07:30 – 17:00**      **Registration (Regency Foyer)**

**07:30 – 08:30**      **Breakfast**

**Location: Regency Ballroom**

**08:30 – 10:00**      **Vaccine / H1N1 symposium**  
**Policy/Epidemiology/Media lessons learned**  
**(Sponsored by GlaxoSmithKline Inc.)**  
Chair: Nigel Rawson, GlaxoSmithKline Inc.

**Speakers:**

**Epidemiology challenges in pandemic response**  
Allison McGeer, Professor, Mount Sinai Hospital, Toronto

**Ethical challenges in pandemic response**  
Cécile Bensimon, Post-doctoral Fellow, Joint Centre for Bioethics,  
University of Toronto, Toronto

**Media lessons learned in pandemic response**  
Don Low, Microbiologist-in-Chief, Mount Sinai Hospital, Toronto

**10:00 – 10:30**      **Break & Contributed Poster Presentations**  
**Location: Regency Foyer & Regency Ballroom West**

**10:30 – 12:00**      **Concurrent Sessions – Contributed Oral Presentations**

**Concurrent Session 1:**  
**Pharmacoepidemiology**  
**Location: Regency Ballroom East**

Chair: Nancy Risebrough, Oxford Outcomes

**Rheumatoid arthritis and serious infections: a nested case-control study from the Ontario Biologics Research Initiative (OBRI)**  
S Bernatsky, McGill University (Abstract 11)

**Under-use of disease-modifying anti-rheumatic drugs for seniors with early rheumatoid arthritis: a population based study from the Ontario Biologics Research Initiative (OBRI)**

C Bombardier, University of Toronto (Abstract 15)

**Antipsychotic-induced cerebrovascular events in the elderly residents of Manitoba: a population-based cohort study**

I Vasilyeva, University of Manitoba (Abstract 3)

**Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors**

SM Cadarette, University of Toronto, Brigham and Women's Hospital, Harvard Medical School (Abstract 1)

**Are we treating wheeze with bug killer?**

C Marra, University of British Columbia (Abstract 4)

**Effectiveness of antihypertensive agents in the secondary prevention of vascular events among patients with ischemic stroke – a nested case-control study**

S Perreault, University of Montreal (Abstract 8)

**Concurrent Session 2:**

**Novel Approaches to outcomes research, epidemiology, and decision-making**

**Location: Regency Ballroom Centre**

Chair: Nicole Mittmann, HOPE Research Centre

**An open-source, interactive model to assess the outcomes and economics of diabetes interventions**

J Hornberger, Stanford University and Cedar Associates LLC (Abstract 2)

**The importance of adjusting for potential confounders when combining evidence from randomised and non-randomised studies: a Bayesian hierarchical model**

CE McCarron, McMaster University and PATH Research Institute (Abstract 14)

**Use and misuse of IV pantoprazole in paediatric inpatients**

E Lau, Hospital for Sick Children (Abstract 16)

**Electronic vascular risk decision support: COMPETE III randomized trial**

AM Holbrook, McMaster University (Abstract 9)

**Using GIS maps to interpret patterns of contraceptive use among youth across British Columbia**

P Raj, University of British Columbia (Abstract 17)

**Confounding and participation effect in a primary care cluster randomised controlled trial on dyslipidemia prescribing practices of physicians**

L Lalonde, University of Montreal (Abstract 5)

**12:00 – 13:30**

**Lunch (Sponsored by Eli Lilly Canada Inc.) & CAPT Annual General Meeting**

All conference attendees are encouraged to participate.

**13:30 – 15:00**

**New Methodologic Frontiers – Pharmacoepidemiology and Pharmacoeconomics**

Chair: Carlo Marra, University of British Columbia

**Speakers:**

**Frontiers in Pharmacoepidemiology**

Sebastian Schneeweiss, Associate Professor, Brigham and Women's Hospital / Harvard Medical School, Boston

**Frontiers in Pharmacoeconomics**

Murray Krahn, Senior Scientist, University of Toronto, Toronto

**15:00 – 15:30**

**Break & Contributed Poster Presentations**

**15:30 – 17:30**

**Observational vs. experimental evidence to inform policy  
The RCT vs observational study debate (Sponsored by SanofiAventis)**

**Moderator:**

Robert Peterson, Executive Director, Drug Safety and Effectiveness Network, CIHR, Ottawa

**Speakers:**

Ken Bassett, Professor, University of British Columbia, Vancouver

David Juurlink, Associate Professor, Sunnybrook Health Sciences Centre, Toronto

**18:30 – 21:00**

(Doors Open at 18:15)

**CAPT Social & Networking Event (Ticket Required)**

**Location: Royal Ontario Museum  
(Sponsored by Takeda Canada, Inc.)**

**Speaker:**

Ms. Helen Stevenson, Ontario Public Drug Programs, Toronto



**07:30 – 12:30            Registration (Regency Foyer)**

**07:30 – 08:30            Breakfast**

**08:30 – 10:00            Novel assessment frameworks to improve decision-making  
(Sponsored by Amgen)**

Chair: Frances Hall, Health Canada

**Speakers:**

**The Economics of Evaluating New Technologies**

Tomas Philipson, Professor, University of Chicago, Chicago

**Difficult Decision-Making at the User Interface: Why the Traditional  
Approach Doesn't Work**

Janet Martin, Assistant Professor, London Health Sciences Centre,  
London, ON

**10:00 – 10:30            Break**

**10:30 – 11:45            Hot Topics in the Canadian Environment**

Chair: Bonnie Cochrane, NL Centre for Health Information

**1. Update on the Canadian Drug Safety and Effectiveness Network  
Initiative**

Robert Peterson, Executive Director, Drug Safety and Effectiveness  
Network, CIHR, Ottawa

**2. Quantitative benefit-risk analysis in regulatory decision-making**

Larry Lynd, Associate Professor, University of British Columbia,  
Vancouver

**11:45 – 12:00            CAPT Awards Ceremony / Conference Close**

Angela Rocchi, Axia Research and President-Elect, Canadian  
Association for Population Therapeutics

**12:00 – 12:30            Buffet Lunch  
(Open to all conference registrants)**

12:30 – 14:30

**Pfizer Canada Satellite Symposium (Pre-Registration Required)**  
**Assessing the value of new therapies: where do we go from here?**

**Objectives of the symposium:**

- 1) Share and exchange diverse perspectives on the current health technology assessment (HTA) processes and frameworks
- 2) Describe and discuss the challenges and strengths with the current HTA framework
- 3) Debate potential solutions and new approaches to improve the HTA framework for the medicines of the future

Chair: Scott Gavura, Director Provincial Drug Reimbursement Programs, Cancer Care Ontario

**Panelists:**

Amir Attaran, Canada Research Chair in Law, Population Health and Global Development Policy, Faculties of Law and Medicine; University of Ottawa; ***providing the legal perspective***

Durhane Wong-Rieger, Chair, Consumer Advocare Network; ***providing the patient perspective***

Jens Grueger, VP Global, Market Access, Pfizer; ***providing the Industry perspective***

Margaret Somerville, Founding Director, McGill Centre for Medicine, Ethics and Law; ***providing the ethical perspective***

Mona Sabharwal, Senior Manager Drug Benefits Management, Ontario Public Drug Programs; ***providing the payer perspective***

---

## ORAL PRESENTATIONS

---

(Note: Presenting Authors are underlined)

1

Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA **Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors**

2

Hornberger J, Shewade A, Rickert J, Hammer M, Groleau D, Adams J **An open-source, interactive model to assess the outcomes and economics of diabetes interventions**

3

Vasilyeva I, Alessi-Severini S, Biscontri RG, Metge C, Collins DM, Enns MW **Antipsychotic-induced cerebrovascular events in the elderly residents of Manitoba: a population-based cohort study**

### 4 – ENCORE PRESENTATION

Marra C, Marra F, Richardson K, Lynd L, FitzGerald JM **Are we treating wheeze with bug killer?**

5

Lalonde L, Blais L, Berbiche D, Villeneuve J, Perreault S, Genest J, Hudon E, Lussier MT, Vanier MC, Lamarre D **Confounding and participation effect in a primary care cluster randomised controlled trial on dyslipidemia prescribing practices of physicians**

6

Donnan JR, Ungar WJ, Mathews M, Rahman P **Cost-effectiveness analysis of thiopurine methyltransferase testing to guide mercaptopurine starting doses in pediatric patients with acute lymphoblastic leukemia**

7

Mittmann N, Isogai P, Rachlis A, Rueda S, Rosenes R, Bayoumi A, Risebrough N, Koo M, Rourke S **Differences in EuroQol Five Dimension (EQ-5D) and Health Utilities Index 3 (HUI3) derived utility scores in an HIV population**

8

Perreault S, Côté R, Dragomir A **Effectiveness of antihypertensive agents in the secondary prevention of vascular events among patients with ischemic stroke – a nested case-control study**

9

Holbrook AM, Pullenayegum E, Thabane L, Keshavjee K, Chan D, Dolovich L, Troyan S, Foster G **Electronic vascular risk decision support: COMPETE III randomized trial**

10

Morgan S, Hanley G, Cunningham C, Quan H **Ethnic disparities in prescription drug use: evidence from British Columbia**

11

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C **Rheumatoid arthritis and serious infections: a nested case-control study from the Ontario Biologics Research Initiative (OBRI)**

12

Woolcott JC, Khan KM, Anis AH, Marra CA **Seniors presenting to the Emergency Department after a fall: costs and consequences**

13

Sedelnikova M, Modha R, Lock K, Howard P **Surrogate outcomes in HTA decision making**

14

McCarron CE, Pullenayegum EM, Thabane L, Goeree R, Tarride JE **The importance of adjusting for potential confounders when combining evidence from randomised and non-randomised studies: a Bayesian hierarchical model**

15

Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C **Under-use of disease-modifying anti-rheumatic drugs for seniors with early rheumatoid arthritis: a population based study from the Ontario Biologics Research Initiative (OBRI)**

16

Lau E, Pai N, Walsh CM, Marcon M **Use and misuse of IV pantoprazole in paediatric inpatients**

17

Raj P, Soon JA, Shoveller J **Using GIS maps to interpret patterns of contraceptive use among youth across British Columbia**

---

## POSTER PRESENTATIONS

---

18

Seung SJ, Mittmann N **A survey of Canadian stakeholders about OctreoScan utilization**

19

Seung SJ, Mittmann N, Sharma M, and The BURST Study Investigators **Resource use after an ischemic stroke: results from The BURST Study**

20

Dolovich L, Levine M, Holbrook A, Thabane L, Nair K, Riemersma K **A systematic review of interventions that optimize medication prescribing and use in Canada**

21

Dolovich L, Levine M, Holbrook A, Thabane L, Raina P, Rangachari P, Goeree R, Nair K, Riemersma K **CIHR Training Program in Bridging Scientific Domains in Medication Safety and Effectiveness: program concepts and development**

22

Mittmann N, Evans WK, Rocchi A, Longo CJ, Au H-J, HuserEAU D, Leighl N, Isogai P, Krahn M, Peacock S, Marshall D, Coyle D, Malfair Taylor SC, Jacobs P, Oh PI **Addendum to CADTH's guidelines for the economic evaluation of health technologies: specific guidance for oncology products**

23

Chan BCF, McLean D, Bell M, Shear NH, Bell H, Mittmann N **One-year drug retention in etanercept patient support program enrollees**

24

Ferrusi IL, Marshall DA, Earle C, Trudeau M, Leighl NB, Pullenayegum E **How are breast cancer testing practices for personalised medicine documented in Ontario? A retrospective review of coded surgical pathology reports**

25

Marra F, Kaczorowski JA, Marra CA **Assessing pharmacists' preparedness for delivering the pandemic influenza vaccine in B.C.**

26

Rance L, Hwang P **Association of co-payments with compliance and employee sick days/short-term disability (ACCESS): a real-world, randomized study**

27

Guertin JR, Dorais M, Sauriol L, Matteau A, Poulin F, Khairy P, Roy D, LeLorier J **Atrial fibrillation: A real life observation study in the Quebec population**

28

Thorne C, Cividino A, Widdifield J, Paterson M, Pope J, Bernatsky S, Li X, Ashoor H, Cesta A, Bombardier C **Baseline characteristics & preliminary efficacy results of patients receiving biologic and traditional disease modifying anti-rheumatic drugs (DMARDs) in Ontario: results from the OBRI**

29

Lynd L, Marra C, Sin D, Harvard S, Liu J, Grubisic M, FitzGerald JM **Benefit-risk analysis of combination LABA + ICS versus increased-dose ICS in treatment of asthma using the incremental net benefit framework**

30

Sadatsafavi M, Marra CA, Lynd LD, Marra F, Liu J, Mendoza O, Tan M, Elwood KR, Fitzgerald JM **Benefit-risk analysis of isoniazid (INH) for treatment of latent tuberculosis infection (LTBI)**

31

Petrella R, Mak D, Ferrazzi S, Kleinstiver P **Chronic obstructive pulmonary disease (COPD) prevalence, disease severity, related healthcare resource utilization in Southwestern Ontario**

32

Hopkins M, Brownrigg R, Magner P **Conversion from epoetin alfa to darbepoietin alfa may be cost-saving in Canadian dialysis patients**

33

Grima D, Mendelssohn D, Airia P, Dunn E, Bernard L **Cost-effectiveness analysis of sevelamer for the treatment of hyperphosphatemia in older Canadian patients with end-stage renal disease**

34

Kamdeu Fansi AA, Guertin JR, Li G, Harasymowycz PJ, Rhame E, LeLorier J **Cost-effectiveness of different modes of screening for open angle glaucoma in glaucoma high-risk populations**

35

Kröger E, van Marum R, Souverein P, Egberts T **Discontinuation of cholinesterase inhibitors: an administrative database study from the Netherlands**

36 – ENCORE PRESENTATION

Deal K, Marshall DA, Dabrowski D, Ciobanu A, Bukoski M, Moayyedi P **Discrete choice experiment to determine willingness-to-pay for gastroesophageal reflux disease (GERD) treatment**  
37

Isogai P, Cheung M, Mittmann N **Economic analysis of alemtuzumab in fludarabine-refractory and relapsed chronic lymphocytic leukemia in Canada**

38

O'Reilly D, Pasricha A, Sauriol L, Metge C, LeLorier J, Healey J, Humphries K, Dorian P, Jacobs P, Tarride J-E, Hopkins R, Xie F, Goeree R **Economic burden of illness study of Atrial Fibrillation (AF) in Canada**

39

O'Reilly D, Blackhouse G, El-Hadi W, Goeree R **Using the Cardiff Long Term Model to estimate the long-term cost-utility of adding Onglyza™ (saxagliptin) versus a thiazolidinedione (TZD) in patients with type 2 diabetes mellitus (T2DM) with insufficient glycemic control using maximal doses of metformin monotherapy and after failure or contraindication to sulfonylurea combination therapy.**

40

Paradis PE, Carter V, Mishagina N, Raymond V **Economic impact of delays in listing decisions by provincial drug plans following a positive Common Drug Review recommendation: the case of a smoking cessation treatment (varenicline)**

41

Cowan CD, Po P, Abdallah M **Effect of a two-tier formulary on prescription drug-utilization and spending: evidence from Canadian employer-sponsored drug plans**

#### **42 – ENCORE PRESENTATION**

Wang M, Marra C, Richardson K, Elwood K, Fitzgerald M, Marra F **Fluoroquinolone and other antibiotics delay diagnosis of tuberculosis**

43

Forte L, Hughes E **Funding IVF for infertile Canadians: a cost-effectiveness analysis**

44

WITHDRAWN

45

Simonyi S, Jog M, Beauchamp R, Miller R, Bhogal M, Wein T **Impact of botulinum toxin type a (BOTOX®) on health utility in patients receiving treatment for approved therapeutic indications: baseline characteristics and interim results of a large ongoing phase iv prospective observational cohort study (MDs on BOTOX® utility-mobility) in Canada**

46

Po P, Law M, Cowan CD, Abdallah M **Impact of Ontario drug formulary listing on drug utilization under privately-insured drug plans**

47

Taylor DW, MacLeod SM, Rieder M, Turgeon J, Ridgway A, Thorpe R, Thomas A, Veenhuizen MF, West A **Key learning points for physicians, pharmacists and patient groups from a clinical roundtable on subsequent entry biologics**

48

Street C, Hodgkinson K, Perrot-Daley A, Sturge M, Young T, West R, Rahman P, Pullman D **Knowledge of your family history could save your life – using information technology to link genealogical information to prevent sudden cardiac death**

49

Longo CJ **Out-of-pocket costs for cancer related drugs: effects of multiple health services deductibles on perceived patient burden in Ontario**

50

Cunningham CM, Hanley GE, Morgan SG **Patterns in the use of benzodiazepines in British Columbia: Examining the impact of increasing research and guideline cautions against long-term use**

51

Marshall DA, Ferrusi IL, Kulin NA, Phillips KA **Personalized medicine and the translation of research into practice**

52

Lessard M, Roy L, Dragomir A, Perreault S **Population-based study: impact of adherence level of antihypertensive agents on onset of end-stage renal disease**

53

Tremblay E, Gaudet M **Prevalence of potentially inappropriate prescriptions (PIPs) in Québec's elderly population, 2000-2006**

54

Lalonde L, Bélanger D, Duhamel F, Goudreau J, Hudon E, Lussier M-T, Martin E, Levesque L **Preventing cardiovascular disease in primary care: priorities for action**

55

Sproule J, Jonsson E, Chuck A **Prioritizing research in evaluation**

56

Martin E, Lalonde L, Choinière M, Dion D, Lussier D, Perreault S, Jouini G, Marchand S **Programme ACCORD: disability and loss of productivity in primary care patients with non-cancer chronic pain**

57

Leroux-Lapointe V, Choinière M, Dion D, Lamarre D, Thiffault R, Lussier D, Martin E, Jouini G, Perreault S, Marchand S, Lalonde L **Programme ACCORD: knowledge, attitudes and beliefs of community pharmacists about non-cancer chronic pain**

58

Jouini G, Choinière M, Dion D, Martin E, Lussier D, Perreault S, Marchand S, Lalonde L **Programme ACCORD: validation of a French version of the pain treatment satisfaction scale in primary care patients with non-cancer chronic pain**

59

Gagnon E **Release of pharmaceuticals into the environment by consumers: a Canadian perspective**

60

Costa-Scharplatz M, Jensen MM, Liovas A **Long-term cost-effectiveness of rosuvastatin compared with generic atorvastatin in a Canadian health care setting**

61

Folia C, Liovas A **Review of studies evaluating the impact of policy-driven statin switch programs on patients**

62

Gamble JM, Eurich DT, Ezekowitz JA, Kaul P, Hude Q, McAlister FA **Sex differences in one-year mortality in people with heart failure among urban and rural residences in Alberta, Canada**

63

Tarride J-E, Haq M, Xie F, Bowen J, Blackhouse G, O'Reilly D, Goeree R **The burden of osteo-arthritis in Ontario**

64

Tarride J-E, Haq M, O'Reilly D, Bischof M, Xie F, Bowen J, Blackhouse G, Goeree R **The burden of rheumatoid-arthritis in Ontario**

65 – ENCORE PRESENTATION

Najafzadeh M, Marra CA, Lynd LD, Sadatsafavi M, Sin DD **The economic value of a potential biomarker for chronic obstructive pulmonary disease**

66

Guertin JG, Dorais M, Sauriol L, Matteau A, Poulin F, Khairy P, Roy D, LeLorier J **The use of amiodarone in Quebec between January 1998 and April 2009. An observational study**

67

Guénette L, Gaudet M, Tremblay É **The use of lipid-lowering drugs in Québec from 2004 to 2008: a cohort study**

68

Metge CJ, Azimee M, Lix L, Morin S, Caetano P, Leslie WD **Using cost-of-illness analysis to describe the direct burden of fracture: estimates of potential savings from prevention**

69

Singh S, Belanger D, Cameron C **Using mixed treatment comparisons to generate recommendations for optimal use of medications**

70

Dragomir A, Angers J-F, Tarride J-E, Rouleau G, Drapeau P, Perreault S **Validation of a Monte-Carlo Markov model for schizophrenia**

71

Marin-Leblanc M, Perreault S, Dubé MP **Validation of warfarin pharmacogenetic algorithms in real clinical practice: preliminary results**

72

Smith LM, Lévesque LE, Nasr M, Perry AG **Validity of the immunization record information system (IRIS) database for epidemiologic studies of the human papillomavirus (HPV) vaccine**

73

Holbrook AM, Dua M, Nikitovic M, Troyan S, Pulleneyagum E, Crowther M **Will individualized benefit-harm risk information affect patients' decisions regarding warfarin**





CONFERENCE

THANK YOU TO OUR SPONSORS FOR YOUR SUPPORT

PLATINUM



GOLD



SILVER



BRONZE

